ENTITY
Catalent Inc

Catalent Inc (CTLT US)

25
Analysis
Health CareUnited States
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics and consumer health products. The Company's oral, injectable, and respiratory delivery technologies address the diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products.
more
bullishCatalent Inc
04 Sep 2017 07:24

New Stem Cell Treatment for Parkinsons Positive for Catalent and Eisai

A pioneering new stem cell treatment with the 'potential to cure Parkinson's disease' has been crafted by researchers. In trials on laboratory...

bullishWuxi Biologics
01 Jun 2017 09:29

WuXi Biologics IPO Review - An Opportunity to Get Exposure to Biologics in China

WuXi Biologics (2269 HK) is looking to raise US$461-511m through the issuance of primary (88%) and secondary (12%) shares.  Proceeds will be used...

Share
bearishWuxi Biologics
27 May 2017 01:58

WuXi Biologics: Pass on This Valuation

The company's underwriters have announced a price range of HK$18.60 - HK$20.60 which implies a market cap of US$2.7-3.0 billion. We recommend...

Share
bullishWuxi Biologics
17 May 2017 05:40

WuXi Biologics: Updated Valuation Data

We have heard that WuXi Biologics' bankers are preparing to move forward with the offering though a PHIP has not been posted yet.  The updated...

Share
bullishWuxi Biologics
15 Feb 2017 01:41

An Early Look at WuXi Biologics

WuXi Biologics, a CRO/contract manufacturer focused on biologics, has filed an Application Proof with the HKEX for a new listing.  The document...

Share
x